Bavarian Nordic — Marts 2021
-
Nyhederne har vist ikke helt forstået godkendelsen. De skriver der er en godkendelse af medfødt hyperinsulism, men det er produktet CHI der retter sig mod den sygdom. Det er hypopal pennen der er blevet godkendt, og det produkt retter sig mod en lidt anden sygdom.
-
Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes
Company announcement – No. 16 / 2021 Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe...
GlobeNewswire News Room (www.globenewswire.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
(dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with Diabetes